OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity
Aakash Desai, Himsikhar Khataniar, Jana G. Hashash, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 6
Aakash Desai, Himsikhar Khataniar, Jana G. Hashash, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 6
Showing 6 citing articles:
Review article: Evidence‐based dietary management of inflammatory bowel disease
Peter R. Gibson, Chu K Yao, Emma P. Halmos
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1215-1233
Open Access | Times Cited: 9
Peter R. Gibson, Chu K Yao, Emma P. Halmos
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1215-1233
Open Access | Times Cited: 9
Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
Aakash Desai, Jessica C. Petrov, Jana G. Hashash, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 5, pp. 620-632
Closed Access | Times Cited: 5
Aakash Desai, Jessica C. Petrov, Jana G. Hashash, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 5, pp. 620-632
Closed Access | Times Cited: 5
Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease
Lindsay Clarke, Ravi Teja Passam, Bryn Falahee, et al.
Digestive Diseases and Sciences (2025)
Closed Access
Lindsay Clarke, Ravi Teja Passam, Bryn Falahee, et al.
Digestive Diseases and Sciences (2025)
Closed Access
Management of Atherosclerotic Cardiovascular Risk in Inflammatory Bowel Disease: Current Perspectives
Walter Masson, Gonzalo Fernández-Villar, Solange Martinez-Elhelou
Advances in Therapy (2025)
Open Access
Walter Masson, Gonzalo Fernández-Villar, Solange Martinez-Elhelou
Advances in Therapy (2025)
Open Access
GLP-1 analog use is associated with improved disease course in inflammatory bowel disease: a report from the Epi-IIRN
Yuri Gorelik, Itai Ghersin, Rona Lujan, et al.
Journal of Crohn s and Colitis (2024)
Open Access | Times Cited: 2
Yuri Gorelik, Itai Ghersin, Rona Lujan, et al.
Journal of Crohn s and Colitis (2024)
Open Access | Times Cited: 2
Efficacy and Safety of Glp-1 Agonists on Metabolic Parameters in Non-diabetic Patients With Inflammatory Bowel Disease
Joëlle St‐Pierre, Jeremy Klein, Natalie K. Choi, et al.
Research Square (Research Square) (2024)
Open Access
Joëlle St‐Pierre, Jeremy Klein, Natalie K. Choi, et al.
Research Square (Research Square) (2024)
Open Access
Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease
Joëlle St‐Pierre, Jeremy Klein, Natalie K. Choi, et al.
Digestive Diseases and Sciences (2024) Vol. 69, Iss. 12, pp. 4437-4445
Closed Access
Joëlle St‐Pierre, Jeremy Klein, Natalie K. Choi, et al.
Digestive Diseases and Sciences (2024) Vol. 69, Iss. 12, pp. 4437-4445
Closed Access
